The International Academy of Clinical Research (IAoCR) has now released its draft GxP Training Guidelines for public consultation following initial review and feedback from over 35 not-for-profit and membership organisations around the world.
Over 60 training and quality assurance personnel have already requested a copy of the draft GxP Training Guidelines which are being made freely available by the IAoCR in order to involve the widest number of interested parties from within the clinical research industry.
As CEO at IAoCR, Jacqueline Johnson North explains: “We have always felt that it is crucial to engage the entire industry in order to create the most cohesive, relevant set of GxP Training recommendations possible. The more people who review this document and provide feedback, the more valuable it will be to all of us. We would like these training guidelines to be applicable to all members of the industry across all sectors and we actively encourage everyone to get involved. We are very pleased with the interest shown to date and hope this accurately reflects the level of commitment from the industry.”
Following the launch of this initiative, executives from the IAoCR have been invited to speak at a number of conferences later this year and on into 2013. Jacqueline will be speaking at the European Training Conference in Lisbon in April 2013 and the IAoCR’s Principal Director, Martin Robinson will be speaking at the French Biomedical Data Management Association conference in Paris in November 2012.
The GxP Training Guidelines have been produced by the International Academy of Clinical Research with input from an independent taskforce of industry experts from the international clinical research community. The aim of the Guidelines is to provide best practice recommendations for the training life-cycle to enable organisations to be able to demonstrate individuals’ competence. The document contains minimum requirements for best practice in training and will be used to help introduce consistent training standards across the industry. It is hoped that the guidelines will be voluntarily adopted across the industry and that this will provide a global framework for best practice.
To receive a copy of the draft Guidelines and information on how to provide feedback complete the webform on www.iaocr.com/gxpt The deadline for feedback is 30 September 2012. After this time, the guidelines will be finalised ready for publication in October 2012.
For more information, please visit www.iaocr.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.